Trial Profile
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Young and Elderly Healthy Male/Female Volunteers (Randomized, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Osoresnontrine (Primary)
- Indications Psychiatric disorders
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 19 Mar 2018 Safety, tolerability and pharmacokinetic (PK) data from three phase I trials (NCT01505894, NCT01611311 and NCT01841112) where repeat doses of BI 409306 were administered to healthy subjects, published in the European Neuropsychopharmacology.
- 25 Sep 2012 New trial record